Mesothelioma Case Study: Keytruda Side Effect Treated with Plasma Exchange

Keytruda side effectGerman mesothelioma doctors say a Keytruda side effect that causes the heart to swell can be treated by “cleaning” the blood plasma. 

The team shared the details of a recent mesothelioma case in Translational Lung Cancer Research. The mesothelioma patient developed a condition called myocarditis after treatment with pembrolizumab (Keytruda). 

The Keytruda side effect is rare but serious. The good news is that cleaning the blood through a process called plasmapheresis restored the patient’s heart function. The article could help other doctors if any of their mesothelioma patients have similar problems.  

Myocarditis as a Keytruda Side Effect

Keytruda is a type of immunotherapy drug called an immune checkpoint inhibitor. It is approved to treat patients who have already tried other mesothelioma therapies. 

Immune checkpoint inhibitors disable a mechanism cancer cells use to protect themselves. In the case of mesothelioma, the protection comes from overexpression of the protein PD-1. Keytruda blocks PD-1. 

But this powerful drug can also cause complications. The German case study focused on a rare but serious Keytruda side effect called myocarditis. Myocarditis is when the heart muscle swells and is not able to pump as much blood as it should. 

Myocarditis can cause shortness of breath, chest pain, weakness, and rapid or abnormal heart rhythms. Viral infections are the most common cause. But it can also be a side effect of mesothelioma treatment. 

German Team Finds Success with Plasmapheresis

The 75-year-old pleural mesothelioma patient in the German case study came in with muscle weakness, shortness of breath, double vision, and drooping eyelids. Doctors suspected a heart problem. Tests showed that certain cardiac biomarkers were elevated. But the patient had no history of heart disease. 

The patient had recently completed two cycles of mesothelioma treatment with pembrolizumab. The team wondered if the problems could be a Keytruda side effect. 

“Because cardiac catheterization revealed no relevant coronary lesions, immune checkpoint inhibitor-associated myocarditis and MG were suspected,” writes the report’s author, Sanziana R I Schiopu of Ludwig Maximilian University Munich. 

MG is an autoimmune disorder that causes neuromuscular problems.  

Steroids and electrical cardioversion did not help either Keytruda side effect. Doctors eventually tried plasmapheresis. Plasmapheresis involves cycling the liquid part of the blood through a machine to clean it. It is one way to treat MG. 

Ten cycles of plasmapheresis did help the MG. It also resolved the heart-related Keytruda side effect. The mesothelioma patient was alive a year later with no lasting problems. 

“We conclude that patients showing no improvement after steroid therapy for immune checkpoint inhibitor-related myocarditis should be evaluated for plasma exchange, which appears to be an effective treatment option,” concludes Dr. Schiopu.

Immunotherapy shows promise for malignant mesothelioma, which is very hard to treat. Last year, the FDA approved two other immunotherapy drugs as a first-line mesothelioma treatment. 

Source:

Schiopu, S, et al, “Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report”, February, 2021, Translational Lung Cancer Research, https://tlcr.amegroups.com/article/view/49484/html

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…